Inflammation Is Not One Thing: Understanding Gut and Skin Research
Few words in health writing do more work than "inflammation" — or get used more loosely. Marketing treats it as a single villain with an off-switch that peptides can apparently flip. Immunology describes something subtle
Few words in health writing do more work than “inflammation” — or get used more loosely. Marketing treats it as a single villain with an off-switch that peptides can apparently flip. Immunology describes something subtler: a coordinated family of responses — blood vessels, immune cells, chemical messengers — that changes shape with the organ, the trigger and the timing.
Inflammation that protects
When you cut a finger or catch an infection, the innate immune system mounts the acute inflammatory response: blood vessels widen and leak, neutrophils arrive within hours, and signalling molecules orchestrate repair. Redness, heat, swelling and pain are consequences of that mobilisation, not faults in it. Acute inflammation is not a malfunction; it is the body’s first organised attempt to contain damage and clear the cause.
Just as important is what follows. Resolution is not inflammation simply fading — it is an active, engineered shutdown: macrophages switch from attack to clean-up, specialised “stop signals” — lipids and proteins — are produced, and dying neutrophils are cleared before they spill their contents. That is how tissue returns to working order.
When the switch fails
Chronic inflammation is not a longer version of the acute response; it is a failure of the ending. Nathan and Ding’s Cell review names it “nonresolving inflammation”: the initiating stimulus persists, resolution mechanisms underperform, and damaged tissue provokes fresh inflammation in a self-perpetuating loop. The problem in chronic disease is rarely that inflammation happened — it is that it did not turn off. A compound tuned to suppress a useful acute response may be useless in a disease whose defect is failed resolution.
The gut and the skin run different programmes
In the gut, “inflammation” usually means inflammatory bowel disease: two distinct conditions, Crohn’s disease and ulcerative colitis, differing in where they strike and how deeply. Their wiring differs too — TNF and IL-23/IL-17 pathways carry much of the signal — and the decisive proof comes from medicines that have blocked those pathways in randomised controlled trials (our inflammation topic page).
The skin splits just as sharply: psoriasis runs largely on the IL-23/IL-17 axis, atopic dermatitis on a different type-2 programme built around IL-4 and IL-13. Same organ, different immune choreography, different registered treatments. Sharing an immune pathway is not the same as sharing a disease.
Where gut and skin genuinely meet, observational studies find psoriasis over-represented in people with IBD. A 2026 Frontiers in Immunology review calls the relationship “partial immune convergence” — shared TNF and IL-23 signalling upstream, reshaped by each tissue’s architecture — while noting direct causal evidence for a human gut–skin axis remains limited.
Biomarkers are proxies, not verdicts
Blood tests collapse all this into numbers, each measuring something narrower than the disease. C-reactive protein (CRP), made by the liver in response to inflammatory signals, is non-specific: it rises with infections, injuries and common metabolic states, and reviews of CRP testing list false elevations as routine reality. A raised CRP says that something is moving, not what or where.
For the gut, clinicians look instead to faecal calprotectin — a neutrophil protein that can account for up to 60% of the protein in these cells’ cytosol, and which accumulates in stool when neutrophils infiltrate the bowel lining. Meta-analyses support its role in separating IBD from irritable bowel syndrome and in tracking activity, yet a dedicated review of routine practice lists limitations at every step.
Biomarkers and symptoms also disagree in both directions: bowel can be inflamed while blood markers stay normal, and skin inflammation will not register in a stool test. A biomarker measures something related to disease, not the disease itself.
Models are simplifications — with consequences
Every model is a designed simplification. In a dish, immune behaviour is studied on single cell types in flat monolayers; organoids improve realism but capture none of the body’s whole-system regulation.
In mice, the standard colitis model feeds dextran sulfate sodium (DSS), which chemically injures the gut lining; severity swings with dose, strain and microbiome, useful for barrier and repair questions, a poor stand-in for chronic human IBD. The popular psoriasis model paints on imiquimod, a toll-like-receptor-7 activator that produces psoriasis-like inflammation in days, reversing on withdrawal — while human psoriasis is sustained by adaptive immune memory. A 2026 Journal of Investigative Dermatology review argues the imiquimod model shows poor transcriptomic overlap with human disease and has fostered an illusion of efficacy. A result in a model is an instruction to run the next experiment — not a promise about patients. How to read peptide research unpacks what each tier can and cannot tell you.
Why one mechanism is not a treatment
From mechanism to medicine: mechanism → cell studies → animal models → observational human data → randomised controlled trials → regulatory review. Most compounds that clear the early gaps fail later; mechanism alone says nothing about dose, delivery, duration or long-term safety. A mechanism is a hypothesis about benefit; controlled human trials are where that hypothesis meets a whole body. In immunology, that bar was genuinely cleared by TNF, IL-12/23 and IL-17 blockers; it is the standard any compound claiming anti-inflammatory activity — peptides included — should honestly be measured against.
Reading KPV claims in this light
KPV is three amino acids — lysine, proline, valine — the closing fragment (α-MSH(11-13)) of alpha-melanocyte-stimulating hormone, as we explain in what are peptides. Dalmasso and colleagues (Gastroenterology, 2008) showed nanomolar KPV dampens NF-κB and MAP kinase signalling in cytokine-stimulated human gut epithelial cell lines and T cells via the PepT1 transporter, and reduced signs of chemically induced colitis when mice drank it in water. Kannengiesser and colleagues (Inflammatory Bowel Diseases, 2008) found KPV improved weight recovery, colon inflammation and myeloperoxidase activity in two murine colitis models, partly independent of the melanocortin-1 receptor.
That is the verified extent of the chain: cell lines, then mice. Published skin-side work is sparse — mostly cell and rodent wound-healing models — yet consumer claims leap straight to “calms psoriasis” or “heals the gut” in people. Formulation and route matter: tripeptides degrade quickly and the published studies used specific carriers and dosing routes, so a claim omitting compound, formulation and route is not tracking the evidence (our KPV Explained article).
The regulatory picture is sparser still. FDA’s review of bulk substances for compounding places KPV — alongside compounded MOTS-c and injectable GHK-Cu — in its category of substances that may present significant safety risks, noting it has identified no human exposure data for KPV by any route. In South Africa, SAHPRA distinguishes registered medicines — demonstrated quality, safety and efficacy — from compounded preparations; no SAHPRA-registered product contains KPV. For every claim currently circulating, the evidence chain stops at cells and mice; the leap to “medicine in humans” has no published trials behind it.
What we don’t know yet
- Whether KPV reliably reaches human gut or skin tissue in meaningful amounts, surviving digestion.
- Its immunogenicity and long-term safety in humans — precisely the data FDA says are missing.
- Which questions a proper KPV trial would ask: induction or maintenance, gut or skin, which population.
- Why resolution fails in particular individuals, and whether pro-resolution approaches will translate into registered treatments.
- How far the gut–skin axis extends beyond association to tested causation.
Where to go next
To grade any inflammatory claim systematically, work through our evidence guide, which maps the full hierarchy from mechanism to registered medicine.
FAQ
Is chronic inflammation just inflammation that lasts longer? No. A chronic process behaves differently: persistent stimuli, cells that shift into tissue-damaging modes, and — crucially — failed resolution of the initial response. Duration is the symptom of the problem, not the definition.
What is the practical difference between CRP and faecal calprotectin? CRP is liver-made and body-wide, rising for many reasons beyond bowel disease. Calprotectin reflects neutrophils entering the gut lining, so it is far more gut-specific. Clinicians interpret each within a specific clinical context, never as a general grade of “inflammation”.
So a normal blood test means my body is free of inflammation? A single normal CRP does not rule out active disease — gut inflammation can persist while blood markers stay normal — and a raised CRP has many non-disease explanations. Blood tests are evidence a clinician weighs in context, never a standalone verdict.
Has KPV ever been tested in humans? We found no published human trials; FDA’s compounding review notes no identified human exposure data for KPV by any route. The verified evidence base is cell-line and mouse work, mostly published in 2008.
Sources
- FDA. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- Nathan C, Ding A. Nonresolving inflammation. Cell. 2010;140(6):871-882. https://pubmed.ncbi.nlm.nih.gov/20303877/
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. https://pubmed.ncbi.nlm.nih.gov/18061177/
- Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. https://pubmed.ncbi.nlm.nih.gov/18092346/
- Wang X, et al. Shared inflammatory architecture and therapeutic tensions between psoriasis and Crohn’s disease. Front Immunol. 2026;17:1871406. https://pubmed.ncbi.nlm.nih.gov/42433375/
- Smith CC, et al. Reevaluating the Imiquimod Model: A Barrier to Translational Progress in Psoriasis. J Invest Dermatol. 2026;146(2):322-327. https://pubmed.ncbi.nlm.nih.gov/41143763/
- Laserna-Mendieta EJ, Lucendo AJ. Faecal calprotectin in inflammatory bowel diseases: a review focused on meta-analyses and routine usage limitations. Clin Chem Lab Med. 2019;57(9):1295-1307. https://pubmed.ncbi.nlm.nih.gov/30785706/
- SAHPRA. SAHPRA’s position on semaglutide compounded products. https://www.sahpra.org.za/sahpras-position-on-semaglutide-compounded-products/
